1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2)

1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2) is a membrane-associated enzyme of the endoplasmic reticulum that catalyzes the acylation of lysophosphatidic acid (LPA) to form phosphatidic acid (PA), a key intermediate in the biosynthesis of both glycerophospholipids (essential components of cell membranes) and triacylglycerols (major fat storage molecules)[1][2][3][5]. AGPAT2 is highly expressed in adipose tissue and plays a critical role in adipocyte development, differentiation, and lipid homeostasis[1][3].\nMutations in the AGPAT2 gene cause congenital generalized lipodystrophy type 1 (CGL1/Berardinelli-Seip syndrome), characterized by near-absence of adipose tissue from birth, severe metabolic derangements (including insulin resistance), and higher risk of diabetes and liver disease[2][3][5].\nAGPAT2 is not known to be directly targeted by approved therapeutic drugs, but is of intense research interest for understanding adipogenesis, metabolic syndrome, and rare inherited lipodystrophies[2][3].\nNote:\n- No approved drugs are known to selectively interact with or modulate AGPAT2 in humans; it is primarily considered a disease gene and research target rather than a current direct therapeutic target[2][3][4][5].\n- AGPAT2 deficiency is itself a cause of severe disease; inhibition would likely be deleterious rather than therapeutic except in tightly controlled research settings[1][3][5].

Other names

1-acyl-sn-glycerol-3-phosphate acyltransferase betaAGPAT21-AGP acyltransferase 2LPAAT-betaLPLAT2BSCLBSCL1LPAABlysophosphatidic acid acyltransferase betalysophospholipid acyltransferase 2

Not directly targeted by approved drugs; loss-of-function or mutation in AGPAT2 leads to disease by interfering with lipid biosynthesis and adipocyte development